|
|
|
| Efficacy of Zoledronic Acid Combined with Calcium Carbonate D3 in the Treatment of Diabetic Osteoporosis and its Effects on Bone Mineral Density and Bone Metabolism Indexes |
| REN Hua, ZHANG Zhiliang, CAI Wei, et al |
| Luwan Branch, Ruijin Hospital, Medical School of Shanghai Jiaotong University, Shanghai 200020, China |
|
|
|
|
Abstract Objective: To investigate the efficacy of zoledronic acid combined with calcium carbonate D3 in the treatment of diabetic osteoporosis (DOP) and its effects on bone mineral density and bone metabolism indexes. Methods: 110 patients with DOP admitted to our hospital from September 2015 to May 2018 were selected and randomly group. 55 patients in control group were treated with Caltrate D3, and 55 patients in experimental group were given zoledronic acid combined with calcium carbonate D3. The clinical efficacy, bone mineral density, bone metabolism indexes, pain, incidence rate of complications and inflammatory factors were analyzed in the two groups. Results: After treatment, the total effective rate in experimental group (94.54%) was significantly higher than that in control group (80.00%) (P<0.05). After treatment, the bone mineral density values of lumbar vertebrae L1~4, femoral neck, femoral trochanter and Wards triangle region in the two groups were significantly increased compared with those before treatment (P<0.05), and the increases in experimental group were greater than those in control group (P<0.05). There were no significant differences in the levels of bone metabolism indexes of serum phosphorus and serum calcium between the two groups before and after treatment (P>0.05). After treatment, the levels of bone metabolism indexes of bone alkaline phosphatase (BALP), bone gla protein (BGP) and β-collagen fragment (β-CTX) and pain visual analogue scale (VAS) score in the two groups were decreased compared with those before treatment (P<0.05), and the decreases in experimental group were greater than those in control group (P<0.05). During treatment, there was not statistically significant difference between the two groups in the incidence rate of complications (P>0.05). After treatment, the levels of interleukin (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in the two groups were significantly decreased compared with those before treatment, and the decreases in experimental group were greater than those in control group (P<0.05). Conclusion: Zoledronic acid combined with calcium carbonate D3 in the treatment of DOP can increase bone mineral density, inhibit bone resorption, promote bone formation and reduce body inflammation, and is safe and effective.
|
|
|
|
|
|
[1] 蔡敏,林建立,侯建明,等.糖尿病合并骨质疏松症致病因素相关性分析[J].中国实用内科杂志,2016,36(11):979~982.
[2] 刘君英,阎德文,邓建新,等.围绝经期2型糖尿病骨质疏松症治疗中胰岛素与阿仑膦酸钠的联合应用效果观察[J].山东医药,2017,57(19):69~71.
[3] 夏维波.应重视糖尿病性骨质疏松症[J].中国糖尿病杂志,2016,8(1):1~4.
[4] 寿张轩,边平达,金雪,等.唑来膦酸对高龄女性骨质疏松症患者骨密度和血清骨转换标志物的影响[J].中国新药与临床杂志,2017,36(8):67~70.
[5] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,6(7):447~498.
[6] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2~17.
[7] 张云,鲁平.老年2型糖尿病患者合并骨质疏松的相关因素分析[J].中华老年医学杂志,2018,37(4):417~419.
[8] 张艳苹,沈志强.骨质疏松相关信号通路的研究进展[J].中华骨科杂志,2017,37(1):59~64.
[9] 刘冬梅,Mosialou Ioanna,刘建民.糖尿病防治新理念--从骨骼入手[J].中华内分泌代谢杂志,2018,34(7):543~548.
[10] 潘颖,郄素会,刘国强,等.金天格胶囊联合唑来膦酸注射液治疗绝经后糖尿病骨质疏松患者的临床观察[J].中国药房,2016,27(35):4953~4956. |
|
|
|
2020, Vol. 26 
